ロード中...
The Why, what, and How of the New FACT standards for immune effector cells
Novel cellular therapies outside of traditional hematopoietic stem cell transplantation or hematopoietic progenitor cell (HPC) therapy are currently under evaluation in clinical trials across the United States and around the world. Several cellular products, e.g., CD19-directed Chimeric Antigen Rece...
保存先:
| 出版年: | J Immunother Cancer |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5394615/ https://ncbi.nlm.nih.gov/pubmed/28428885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0239-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|